PDFs by language
Our 24/7 cancer helpline provides support for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
At our National Cancer Information Center trained Cancer Information Specialists can answer questions 24 hours a day, every day of the year to empower you with accurate, up-to-date information to help you make educated health decisions. We connect patients, caregivers, and family members with valuable services and resources.
Or ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Gastrointestinal Neuroendocrine (Carcinoid) Tumors
A risk factor is anything that increases your chance of getting a disease such as cancer. Different cancers have different risk factors. Some risk factors, like smoking, can be changed. Others, like a person’s age or family history, can’t be changed.
In some cases, there might be a factor that may decrease your risk of developing cancer. That is not considered a risk factor, but you may see them noted clearly on this page as well.
But having a risk factor, or even many, does not mean that you will get cancer. And some people who get cancer may not have any known risk factors. Here are some of the risk factors known to increase your risk for GI carcinoid tumors.
This is a rare condition caused by inherited defects in the MEN1 gene. People with this syndrome have a very high risk of getting tumors of the pituitary, parathyroid, and pancreas. They also have an increased risk of carcinoid tumors. Some studies estimate that inherited mutations of the MEN1 gene are responsible for about 5% to 10% of carcinoid tumors. Most of these are gastric (stomach) carcinoids. Children have a 50/50 chance of inheriting this syndrome from a parent.
If you have family members with the MEN1 syndrome, you might want to talk to your doctor about the pros and cons of getting tested for it. Although the gene that causes tumors in people with the MEN1 syndrome has been found, the results of genetic testing are not always clear cut so it is important that the test is done along with genetic counseling to help you make sense of the results.
This disease often runs in families and is characterized by many neurofibromas (benign tumors that form in nerves under the skin and in other parts of the body). It is caused by defects in the NF1 gene. Some people with this condition also develop carcinoid tumors of the small intestines.
Carcinoid tumors are also more common among people with tuberous sclerosis complex, von Hippel Lindau disease and familial small intestinal neuroendocrine tumor.
To find out more on being tested for genetic syndromes, see Genetic Testing: What You Need to Know.
Carcinoid tumors are more common among African Americans than whites. Outcomes are also not as good for African Americans. Researchers do not yet know why. Carcinoid tumors are also slightly more common in women than men.
People with certain diseases that damage the stomach and reduce the amount of acid it makes (such as atrophic gastritis or Zollinger-Ellison syndrome) have a greater risk of developing stomach carcinoid tumors, but their risk for carcinoid tumors of other organs is not affected.
Having a family history of any cancer, specifically in a first-degree relative (sibling, parent, or child), or a family history of a neuroendocrine tumor or carcinoid tumor seems to raise the risk of developing a carcinoid tumor.
It is not clear if smoking increases the risk of getting a carcinoid tumor. Further studies are needed.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.
Benafif S and Eeles R. Diagnosis and Management of Hereditary Carcinoids. Recent Results Cancer Res. 2016; 205:149-68. doi: 10.1007/978-3-319-29998-3_9.
Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC. Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):959-65. doi: 10.1158/1055-9965.EPI-07-0750.
Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC. Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. Int J Cancer. 2008 Aug 15;123(4):867-73. doi: 10.1002/ijc.23529.
Kaerlev L, Teglbjaerg PS, Sabroe S, et al. The importance of smoking and medical history for development of small bowel carcinoid tumor: a European population-based case-control study. Cancer Causes Control. 2002;13:27–34.
Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003; 97:934–959.
National Cancer Institute Physician Data Query (PDQ). Gastrointestinal Carcinoid Tumors Treatment (PDQ®)–Health Professional Version. 2018. Accessed at
https://www.cancer.gov/types/gi-carcinoid-tumors/hp/gi-carcinoid-treatment-pdq#section/_21 on July 31, 2018.
Norton JA and Kunz PL. Carcinoid) Tumors and the Carcinoid Syndrome. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2015:1218–-1226.
Schneider DF, Mazeh H, Lubner SJ, Jaume JC, Chen H. Cancer of the Endocrine System. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa: Elsevier; 2014:1112-1142.
Last Revised: September 24, 2018
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.